Page last updated: 2024-11-03

propafenone and Dizzyness

propafenone has been researched along with Dizzyness in 8 studies

Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.

Research Excerpts

ExcerptRelevanceReference
"The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)."9.10Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003)
"The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation was investigated in 16 patients presenting with frequent and/or poorly tolerated paroxysmal atrial fibrillation despite prophylactic treatment in 13 patients."7.68[Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. ( Bru, P; Cointe, R; Gerard, R; Lévy, S; Metge, M; Paganelli, F; Vrancea, F, 1993)
"Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone."7.67Propafenone for the treatment of severe ventricular arrhythmias. ( Bar-Shlomo, B; Boroomand-Rashti, K; Rabkin, SW; Rotem, CE, 1984)
"The objective of this randomized, double-blind, placebo-controlled clinical trial was to test the efficacy and safety of a new sustained-release preparation of the antiarrhythmic drug propafenone (propafenone SR) in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation (AF)."5.10Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. ( Carlson, M; Fava, G; Page, RL; Pritchett, EL; Undesser, K, 2003)
" Three months after starting citalopram, she experienced episodes of chest tightness and dizziness."3.74Adverse effects of propafenone after long-term therapy with the addition of citalopram. ( Garcia, A, 2008)
"The efficacy of propafenone in the treatment of paroxysmal atrial fibrillation was investigated in 16 patients presenting with frequent and/or poorly tolerated paroxysmal atrial fibrillation despite prophylactic treatment in 13 patients."3.68[Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation]. ( Bru, P; Cointe, R; Gerard, R; Lévy, S; Metge, M; Paganelli, F; Vrancea, F, 1993)
"Twenty-one patients whose severe ventricular arrhythmias were not controlled by other currently used antiarrhythmic agents or who were intolerant of those drugs were treated with a new antiarrhythmic agent, propafenone."3.67Propafenone for the treatment of severe ventricular arrhythmias. ( Bar-Shlomo, B; Boroomand-Rashti, K; Rabkin, SW; Rotem, CE, 1984)
"Two patients with recurrences of sustained VT in this group were later successfully treated with propafenone, 900 mg/day; overall, 8 of 9 patients with recurrences of sustained VT were successfully treated with 900 mg/day."1.27Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment. ( Ambrosioni, E; Bracchetti, D; Marchesini, B; Naccarella, F; Palmieri, M, 1984)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's2 (25.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lip, GY1
Fauchier, L1
Freedman, SB1
Van Gelder, I1
Natale, A1
Gianni, C1
Nattel, S1
Potpara, T1
Rienstra, M1
Tse, HF1
Lane, DA1
Garcia, A1
Alexoudis, A1
Spyridonidou, A1
Pritchett, EL1
Page, RL1
Carlson, M1
Undesser, K1
Fava, G1
Rabkin, SW1
Rotem, CE1
Boroomand-Rashti, K1
Bar-Shlomo, B1
Naccarella, F1
Bracchetti, D1
Palmieri, M1
Marchesini, B1
Ambrosioni, E1
Cointe, R1
Metge, M1
Bru, P1
Vrancea, F1
Gerard, R1
Paganelli, F1
Lévy, S1
Cai, WM1
Chen, B1
Cai, MH1
Chen, Y1
Zhang, YD1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546]Phase 4600 participants (Anticipated)Interventional2014-05-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for propafenone and Dizzyness

ArticleYear
Atrial fibrillation.
    Nature reviews. Disease primers, 2016, 03-31, Volume: 2

    Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun

2016

Trials

2 trials available for propafenone and Dizzyness

ArticleYear
Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation.
    The American journal of cardiology, 2003, Oct-15, Volume: 92, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Fibrillation; C

2003
The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
    British journal of clinical pharmacology, 1999, Volume: 47, Issue:5

    Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Area Under Curve; China; Cytochrome P-450 CYP2D

1999

Other Studies

5 other studies available for propafenone and Dizzyness

ArticleYear
Adverse effects of propafenone after long-term therapy with the addition of citalopram.
    The American journal of geriatric pharmacotherapy, 2008, Volume: 6, Issue:2

    Topics: Accidental Falls; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Dizzin

2008
Images in emergency medicine. Reversible QRS complex widening after oral administration of propafenone.
    Emergency medicine journal : EMJ, 2010, Volume: 27, Issue:11

    Topics: Administration, Oral; Aged; Atrial Fibrillation; Diagnosis, Differential; Dizziness; Electrocardiogr

2010
Propafenone for the treatment of severe ventricular arrhythmias.
    Canadian Medical Association journal, 1984, Sep-15, Volume: 131, Issue:6

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dizziness; Female; Humans; Male; Middle A

1984
Propafenone for refractory ventricular arrhythmias: correlation with drug plasma levels during long-term treatment.
    The American journal of cardiology, 1984, Nov-01, Volume: 54, Issue:8

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Dizziness; Female; Humans

1984
[Intravenous and oral propafenone in the treatment and prevention of paroxysmal atrial fibrillation].
    Annales de cardiologie et d'angeiologie, 1993, Volume: 42, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Atrial Fibrillation; Dizziness; Drug Evaluation; Fema

1993